StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The stock has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 12-month low of $0.00 and a 12-month high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- The How And Why of Investing in Oil Stocks
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Lockheed Martin Stock Aims for a Fresh All-Time High
- The 3 Best Fintech Stocks to Buy Now
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.